Tirzepatide and Similar Weight-Loss Medicines: How to Choose

Which UK medicines actually sit in the same category?

The decision most people are really making is between tirzepatide and semaglutide, because those are the two active ingredients licensed in the UK for weight management in adults. Tirzepatide is sold as Mounjaro, a once-weekly injection via a pre-filled KwikPen. Semaglutide for weight loss comes in two forms: the once-weekly Wegovy injection and, since June 2026, the Wegovy tablet taken once daily.

A few names worth clearing up. Ozempic is also semaglutide, but it holds a UK licence for type 2 diabetes, not weight management, it is not interchangeable with Wegovy for weight-loss purposes. Rybelsus is oral semaglutide at lower doses (3mg, 7mg, 14mg), again licensed for diabetes only. Neither belongs in a comparison of weight-loss medicines for most readers arriving at this page.

Orlistat (a lipase inhibitor, available over the counter at lower strength) is a much older option that works entirely differently, reducing fat absorption rather than acting on appetite hormones. It is not a GLP-1 or GIP agonist. For completeness it exists, but most people comparing tirzepatide-similar products are looking at injectable or oral GLP-1 class medicines, where the meaningful choice is between Mounjaro and Wegovy in its various forms. If you want to explore the full range of tirzepatide products available, that page sets out what is currently offered and how the doses are structured.

How the mechanism difference plays out in practice

Tirzepatide's dual action on GIP and GLP-1 receptors is not just a technical detail. In the SURMOUNT-1 trial involving thousands of adults with obesity, average body-weight reduction reached around 20–21% at the 15mg maintenance dose over 72 weeks, figures cited directly in NICE's appraisal of tirzepatide (TA1026). The SURMOUNT-5 head-to-head then compared tirzepatide directly with semaglutide 2.4mg, and tirzepatide produced greater average loss.

Semaglutide 2.4mg (Wegovy injection) showed around 15% average reduction in the STEP 1 trial at 68 weeks. The newer 7.2mg Wegovy pen, approved by the MHRA in April 2026, has produced roughly 20.7% average loss in trials, narrowing the gap with tirzepatide's highest dose considerably.

The oral Wegovy tablet produced around 13.6% average weight loss in the OASIS 4 trial (64 weeks, 307 adults), rising to roughly 17% among participants who adhered fully to treatment. Tablet bioavailability is lower than injection, which accounts for the difference, and the morning routine matters: the tablet needs to be taken on an empty stomach with a small amount of plain water, at least 30 minutes before food or any other oral medicine. One patient described it as the medicine that has to come before the kettle goes on, which is probably the clearest description of the timing rule.

Side-effect profiles are broadly similar across the class: nausea, vomiting, diarrhoea and constipation are the most common, usually most noticeable after starting or a dose increase and settling within days to a couple of weeks. The NHS tirzepatide medicine page covers the full list for Mounjaro. Individual tolerability varies, and that is a genuine clinical variable, not just a caveat.

Eligibility: where tirzepatide and semaglutide differ on paper

For private prescribing, tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Wegovy injection holds a similar threshold. The newer Wegovy tablet requires a BMI of 30 or above, or 27–29.9 with a qualifying condition.

On the NHS, NICE's recommendation for tirzepatide (TA1026) applies to adults with BMI 35 or above plus at least one weight-related comorbidity, with the BMI threshold 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. NICE's recommendation for Wegovy (TA875) is narrower still, it applies only within specialist weight management services for a maximum of two years. If you want a fuller read on how the NHS phased rollout works in practice, the NHS access picture for Mounjaro and comparable medicines is worth reviewing.

None of these thresholds guarantee a prescription. A prescriber looks at the whole clinical picture: contraindications, current medicines, history, and which option is most appropriate for the individual. BMI is one input.

How to weigh up which option is right for you

There is no universally correct answer. Tirzepatide currently shows the strongest average weight-loss figures in trials, but the 7.2mg Wegovy pen narrows that difference meaningfully, and for people who prefer not to inject, the Wegovy tablet is a genuinely different option. A question our prescribers hear regularly: can I switch between them? Yes, but switching is a clinical decision that needs review, not something to self-manage. If you are trying to understand what makes Mounjaro distinct from other options in this class, our page on medicines similar to Mounjaro walks through the comparisons in plain terms.

Cost is a real variable. Treatment prices differ by product and dose, and the full picture of what any price includes (prescription, clinical oversight, aftercare, delivery) matters more than the headline figure. For a fair account of how pricing in this class actually works, the Mounjaro treatment page sets out the context without making claims either direction.

Whichever medicine is right for you, the route is the same: a prescription following a clinical assessment by a qualified prescriber. If you want a clear-eyed conversation about the options, speaking to our prescribers is a good place to start. There is no obligation, and the consultation is free.